

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Yanez Michelle</u> (Last) (First) (Middle) C/O MIRA PHARMACEUTICALS, INC. 900 WEST PLATT STREET, SUITE 200 (Street) TAMPA FL 33606-2173 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/02/2023	3. Issuer Name and Ticker or Trading Symbol <u>MIRA PHARMACEUTICALS, INC. [MIRA]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CFO, Secretary & Treasurer	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (right to buy)	(1)	06/15/2032	Common Stock	10,000	5	D
Stock Option (right to buy)	(2)	04/28/2033	Common Stock	46,667	5	D

Explanation of Responses:

- The option vested and became exercisable as to 3,334 shares on June 15, 2022, and 3,333 shares on June 15, 2023, and becomes exercisable as to the remaining 3,333 shares on June 15, 2024.
- The option vested and became exercisable as to 15,556 shares on April 28, 2023, and becomes exercisable on the remaining 15,556 shares on April 28, 2024 and 15,555 shares on April 28, 2025.

/s/ Michelle Yanez 08/02/2023
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.